​

ImmunityBio (IBRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

ImmunityBio Revenue Highlights

Latest Revenue (Y)

$113.29M

Latest Revenue (Q)

$32.06M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

ImmunityBio Revenue by Period

ImmunityBio Revenue by Year

DateRevenueChange
2025-12-31$113.29M668.31%
2024-12-31$14.74M2270.58%
2023-12-31$622.00K159.17%
2022-12-31$240.00K-74.30%
2021-12-31$934.00K54.38%
2020-12-31$605.00K1306.98%
2019-12-31$43.00K-8.51%
2018-12-31$47.00K4.44%
2017-12-31$45.00K2.27%
2016-12-31$44.00K-81.36%
2015-12-31$236.00K-63.18%
2014-12-31$641.00K6.83%
2013-12-31$600.00K-

ImmunityBio generated $113.29M in revenue during NA 2025, up 668.31% compared to the previous quarter, and up 18725.29% compared to the same period a year ago.

ImmunityBio Revenue by Quarter

DateRevenueChange
2025-09-30$32.06M21.33%
2025-06-30$26.43M59.99%
2025-03-31$16.52M118.71%
2024-12-31$7.55M23.68%
2024-09-30$6.11M483.19%
2024-06-30$1.05M2517.50%
2024-03-31$40.00K-71.22%
2023-12-31$139.00K69.51%
2023-09-30$82.00K100.00%
2023-06-30$41.00K-88.61%
2023-03-31$360.00K393.15%
2022-12-31$73.00K-38.14%
2022-09-30$118.00K237.14%
2022-06-30$35.00K150.00%
2022-03-31$14.00K-96.41%
2021-12-31$390.00K490.91%
2021-09-30$66.00K-80.53%
2021-06-30$339.00K143.88%
2021-03-31$139.00K-194.56%
2020-12-31$-147.00K-197.35%
2020-09-30$151.00K-65.37%
2020-06-30$436.00K164.24%
2020-03-31$165.00K-82.07%
2019-12-31$920.00K7566.67%
2019-09-30$12.00K-29.41%
2019-06-30$17.00K240.00%
2019-03-31$5.00K-28.57%
2018-12-31$7.00K-77.42%
2018-09-30$31.00K675.00%
2018-06-30$4.00K-20.00%
2018-03-31$5.00K-58.33%
2017-12-31$12.00K50.00%
2017-09-30$8.00K-42.86%
2017-06-30$14.00K27.27%
2017-03-31$11.00K-21.43%
2016-12-31$14.00K16.67%
2016-09-30$12.00K-
2016-06-30$12.00K100.00%
2016-03-31$6.00K-57.14%
2015-12-31$14.00K40.00%
2015-09-30$10.00K-89.01%
2015-06-30$91.00K-

ImmunityBio generated $32.06M in revenue during Q3 2025, up 21.33% compared to the previous quarter, and up 3062.18% compared to the same period a year ago.

ImmunityBio Revenue Breakdown

ImmunityBio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
Product$112.98M$14.15M
Product and Service, Other$306.00K$595.00K

ImmunityBio's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (99.73%), and Product and Service, Other (0.27%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24
Product and Service, Other$13.00K$281.00K$4.00K$8.00K$443.00K$152.00K
Product$38.27M$31.78M$26.42M$16.51M$8.20M$5.95M

ImmunityBio's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (99.97%), and Product and Service, Other (0.03%).

ImmunityBio Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23Dec 22Dec 21
UNITED STATES$113.01M$14.21M$31.00K$42.00K$373.00K
Europe$278.00K$531.00K$591.00K$198.00K$561.00K

ImmunityBio's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (99.75%), and Europe (0.25%).

Quarterly Revenue by Country

CountryDec 25Sep 25Jun 25Mar 25Mar 18
Europe$16.00K$262.00K---
UNITED STATES$38.27M$31.80M$26.43M$16.52M-
San Diego California----$100.00K

ImmunityBio's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (99.96%), and Europe (0.04%).

ImmunityBio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RCUSArcus Biosciences$247.00M$26.00M
GLPGGalapagos$239.70M$62.43M
LQDALiquidia$158.32M$54.34M
IBRXImmunityBio$113.29M$32.06M
RXRXRecursion Pharmaceuticals$74.68M$5.17M
VRDNViridian Therapeutics$70.85M$70.57M
AGIOAgios Pharmaceuticals$54.03M$12.88M
COGTCogent Biosciences--
BEAMBeam Therapeutics--
DNLIDenali Therapeutics--

IBRX Revenue FAQ

What is ImmunityBio’s yearly revenue?

ImmunityBio's yearly revenue for 2025 was $113.29M, representing an increase of 668.31% compared to 2024. The company's yearly revenue for 2024 was $14.74M, representing an increase of 2270.58% compared to 2023. IBRX's yearly revenue for 2023 was $622K, representing an increase of 159.17% compared to 2022.

What is ImmunityBio’s quarterly revenue?

ImmunityBio's quarterly revenue for Q3 2025 was $32.06M, a 21.33% increase from the previous quarter (Q2 2025), and a 425.07% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $26.42M, a 59.99% increase from the previous quarter (Q1 2025), and a 2423.88% increase year-over-year (Q2 2024). IBRX's quarterly revenue for Q1 2025 was $16.52M, a 118.71% increase from the previous quarter (Q4 2024), and a 41192.50% increase year-over-year (Q1 2024).

What is ImmunityBio’s revenue growth rate?

ImmunityBio's revenue growth rate for the last 3 years (2023-2025) was 18113.50%, and for the last 5 years (2021-2025) was 12029.34%.

What are ImmunityBio’s revenue streams?

ImmunityBio's revenue streams in c 25 are Product, and Product and Service, Other. Product generated $112.98M in revenue, accounting 99.73% of the company's total revenue, up 698.46% year-over-year. Product and Service, Other generated $306K in revenue, accounting 0.27% of the company's total revenue, down -48.57% year-over-year.

What is ImmunityBio’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of ImmunityBio was Product. This segment made a revenue of $112.98M, representing 99.73% of the company's total revenue.